ZILRETTA® Practice Toolkit | Implementation Resources

PRACTICE TOOLKIT

A variety of ZILRETTA education and support resources for you, your community, and your patients.

Downloading...0%

Download the ZILRETTA Practice Toolkit

Select from below to download any or all available ZILRETTTA resources.

*Required Field

Select All

FlexForward^® SupportComprehensive access assistance designed to help your eligible patients get started with ZILRETTA

Patient ToolsBrochure and flashcard to help introduce ZILRETTA to your patients

Claims SupportMaterials to help assist you, your office staff, and your patients through the claims process for ZILRETTA

Additional AssetsZILRETTA logo and other product images for use on your marketing materials (formatted as PNG, JPG, and PSD files)

First Name Please enter your first name.

Last Name Please enter your last name.

Email Address Please enter your email address.

Facility Name Please enter facility name.

Click here to opt-in to future communications from Pacira BioSciences, Inc.*

Submit

Thank You!

Your download will begin shortly.

This may take several minutes.

Download again

Download again
Form Confirmation Screen

Indication and Important Safety Information

Indication

ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension) is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Important Safety Information

Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Warnings and Precautions

Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
Hypersensitivity Reactions: Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
Joint Infection and Damage: A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
Increased Risk of Infections: Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
Alterations in Endocrine Function: Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
Cardiovascular and Renal Effects: Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
Increased Intraocular Pressure: Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
Gastrointestinal Perforation: Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
Alterations in Bone Density: Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
Behavior and Mood Disturbances: Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.

Adverse Reactions
The Most commonly reported adverse reactions (incidence ≥1%) in clinical studies include sinusitis, cough, and contusions.

Please see full Prescribing Information.

Practice Toolkit

PRACTICE TOOLKIT

Download the ZILRETTA Practice Toolkit

Thank You!

Your download will begin shortly.

This may take several minutes.